Global Lambert-Eaton Myasthenic Syndrome Drugs and Companies Clinical Trials Review H2 2017

Lambert-Eaton Myasthenic Syndrome Assessment and Therapeutics Clinical Trials Review H2 2017

PUNE, INDIA, January 2, 2018 / -- Pune, India, 2nd December 2017: WiseGuyReports announced addition of new report, titled “Lambert-Eaton Myasthenic Syndrome (LEMS) Global Clinical Trials Review, H2, 2017”.

"Lambert-Eaton Myasthenic Syndrome (LEMS) Global Clinical Trials Review, H2, 2017" provides an overview of Lambert-Eaton Myasthenic Syndrome (LEMS) clinical trials scenario. This report provides top line data relating to the clinical trials on Lambert-Eaton Myasthenic Syndrome (LEMS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Content: Key Points
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Lambert-Eaton Myasthenic Syndrome (LEMS) to Immunology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Lambert-Eaton Myasthenic Syndrome (LEMS) to Immunology Clinical Trials 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics Clinical Trials 26
Prominent Drugs 27
Latest Clinical Trials News on Lambert-Eaton Myasthenic Syndrome (LEMS) 28
Oct 31, 2017: Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse in Patients with Lambert-Eaton Myasthenic Syndrome 28


Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.